While some studies have investigated the effectiveness of exercise interventions during adjuvant chemotherapy in cancer patients, the findings are inconclusive. This systematic review and meta-analysis aimed to quantify the effectiveness of exercise interventions specifically in patients with colorectal cancer (CRC) during adjuvant chemotherapy.

Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a rare and complex cutaneous immune-related adverse event (cirAE) that often impacts the continuation of ICI therapy. Currently, there are no prospective clinical studies addressing the optimal management of BP alongside ICI continuation, with existing evidence largely derived from case reports or series. This study systematically analyzes published case reports and series to compile evidence regarding the management of ICI-BP and ICI rechallenge, aiming to inform clinical practice.

To identify the impact of CT-defined emphysema on efficacy and immune checkpoint inhibitor-related pneumonitis (ICIP) risk among non-small cell lung cancer (NSCLC) patients who receive ICIs.

Breast cancer remains one of the most prevalent malignant tumors affecting women worldwide and continues posing a major threat to global health. Current clinical treatments include surgery, chemotherapy, radiotherapy, targeted therapy, and endocrine therapy. However, these strategies are frequently limited by challenges such as drug resistance, elevated toxicity, adverse effects, and inadequate modulation of the tumor microenvironment (TME). Recent developments in nanotechnology have enabled the application of nanomaterial-based drug delivery systems that significantly improve delivery efficiency and biocompatibility, reduce drug toxicity and side effects, and demonstrate potential anticancer effects by modulating the TME. Hydrogels, a class of drug carriers, are characterized by a three-dimensional polymer network with high water absorption and retention capacity. Owing to their favorable biocompatibility, degradability, tissue-like physical properties, environmental responsiveness, and functional flexibility, hydrogels have been extensively utilized in biomedical applications, including bone regeneration, wound healing, antibacterial treatments, biosensing, and tumor therapy. Despite these advantages, hydrogels and nanomaterials still confront significant challenges when applied in breast cancer therapy. The integration of functional nanomaterials into the hydrogel matrix can form a novel multifunctional system. This transformation allows hydrogels to serve as targeted delivery platforms for anticancer nanodrugs, enabling synergistic therapeutic effects. This systematic review summarizes recent advances in hydrogel-based nanomaterials for breast cancer therapy, with emphasis on design strategies, mechanisms of action, and immunomodulatory applications. It also critically discusses current limitations and prospects of hydrogel-based nanomaterials. The objective of this review is to help lower interdisciplinary barriers and accelerate the clinical translation of hydrogel-based technologies toward safer, more personalized breast cancer treatments.

In proficient mismatch repair (pMMR) non metastatic rectal cancer, standard neoadjuvant chemoradiotherapy (nCRT) yields low pathological and clinical complete response rates. Early randomized trials suggest adding PD 1 inhibitors may increase response but randomized evidence has not been synthesized.

Advances in treating multiple myeloma (MM) have improved survival, shifting the management focus toward quality of life. Peripheral neuropathy (PN) is a common treatment-related toxicity that significantly impairs quality of life. However, standardized assessment methods for PN in patients with MM are currently lacking. A comprehensive search of multiple databases (PubMed, Embase, Cochrane Library, and KoreaMed) was conducted to identify relevant records. Eligible studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Twenty-two studies were included, and 17 PN assessment tools were identified. Nerve conduction studies and the National Cancer Institute Common Terminology Criteria for Adverse Events were the most commonly used clinician-based tools, whereas the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity was the most frequently used patient-reported outcome measure. The use of these tools varies depending on whether their purpose is diagnostic or evaluative. To the best of our knowledge, this is the first systematic review to evaluate PN assessment tools for patients with MM, revealing substantial heterogeneity across studies. By organizing these diverse approaches, our findings can guide researchers and clinicians toward a more consistent and standardized PN evaluation, ultimately improving the management of treatment-related neuropathy in MM.

Stachydrine, a principal bioactive alkaloid derived from Leonurus japonicus (motherwort), has attracted significant interest due to its diverse pharmacological activities and nutritional relevance. This systematic review synthesizes current evidence on its therapeutic potential across multiple organ systems. Stachydrine core pharmacological activities are: Cardiovascular protection: Stachydrine mitigates myocardial ischemia/reperfusion injury by scavenging free radicals, reducing myocardial biomarkers (CK, LDH, cTnT), and enhancing nitric oxide (NO) production. It attenuates pathological ventricular remodeling by suppressing ROS-mediated activation of NF-κB and improves cardiac calcium handling by protecting sarcoplasmic reticulum function. Antitumor effects: In cancers (e.g. hepatocellular carcinoma, breast cancer, colorectal cancer), stachydrine inhibits tumor proliferation, metastasis, and chemoresistance by targeting pathways such as TGF-β/Smad, PI3K/Akt/mTOR, and JAK2/STAT3. It also modulates the tumor microenvironment by reprogramming tumor-associated macrophages. Renoprotective actions: It ameliorates drug-induced renal fibrosis by suppressing tubular cell apoptosis via downregulation of caspase-9/caspase-12 and inhibiting inflammatory cytokine release.

Hyponatremia is the most prevalent electrolyte imbalance in cancer patients. Symptoms potentially signaling hyponatremia include altered mental status, neurological condition, headache, nausea, dizziness, and balance loss. Its management is particularly challenging as it must account for prognosis, treatment-related factors, and quality of life, especially in individuals treated with immune checkpoint inhibitors (ICIs). This systematic review and meta-analysis assessed the incidence of hyponatremia in patients receiving ICIs or immune-based combinations compared with placebo or other anticancer treatments. The review was registered in PROSPERO (CRD420251137412). Eligible studies included randomized clinical trials, quasi-experimental, and observational studies reporting hyponatremia frequency in patients treated with ICIs. Risk of bias was assessed using the ROB 2 tool for randomized studies and ROBINS-I for observational studies. A meta-analysis for proportions was performed using generalized linear mixed models. Proportion was measured for any grade of hyponatremia, grade 1-2, and grade ≥ 3; and three separate subgroup meta-analyses were performed: one for any grade, one for grade 1 or 2, and one for grade ≥ 3. Thirteen studies were included in the quantitative analyses. Any-grade hyponatremia was reported in 7 studies (934 patients, 49 events), with a pooled prevalence of 5.0% (95% CI = [2.3%; 11.9%]; I2 = 81.8%). Grade 1-2 hyponatremia was assessed in 7 studies (314 patients, 36 events) with a pooled prevalence of 1.2% (95% CI = [0.03%; 37.8%]; I2 = 88.2%). Grade ≥ 3 hyponatremia was evaluated in 14 studies (652 patients, 35 events), yielding a pooled prevalence of 5.5% (95% CI = [3.1%; 9.6%]; I2 = 44.8%). No significant small-study effects were detected for grade ≥ 3 events (Egger's test P = 0.313). These findings support routine electrolyte surveillance in patients treated with ICIs and highlight the need for further studies to clarify mechanisms and risk factors and define optimal monitoring strategies to improve both safety and outcomes.

Chemotherapy-induced peripheral neuropathy remains a major complication in pediatric cancer, with disrupted somatosensory and nociceptive processing being a key aspect. This review synthesizes empirical studies on alterations in somatosensory and nociceptive processing in children and adolescents with cancer. We conducted this review in accordance with PRISMA 2020 guidelines and preregistered it in PROSPERO. A systematic search was performed in MEDLINE, CINAHL, and Web of Science in April 2025. Eligible studies were screened by two independent reviewers and synthesized narratively. Risk of bias was assessed using the Newcastle Ottawa Quality Assessment Scale for Case-Control Studies. Nine studies met the inclusion criteria, all using cross-sectional designs and quantitative sensory testing (QST) or other pain protocols. Overall, findings suggest altered somatosensory processing in this population, with higher mechanical and thermal detection thresholds in patients compared to controls. Findings on nociceptive processing were more heterogeneous, with most studies suggesting unaltered pain sensitivity in the lower pain range and increased sensitivity in the higher pain range, highlighting increased pain vulnerability to more intense pain stimuli following cancer and its treatment. This review reveals a pattern of decreased somatosensory processing and increased nociceptive processing in pediatric patients/survivors with cancer, likely attributable to damage of peripheral nervous tissues as well as central sensitization.

Elotuzumab, an anti-SLAMF7 monoclonal antibody for multiple myeloma (MM), lacks a comprehensive safety profile from meta-analysis.

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are complicated by immune-related adverse events, including acute kidney injury (AKI). As clinical experience matures and treatment durations lengthen, initial estimates of ICI-AKI incidence and the perceived risks of resuming therapy may become outdated.

Intravitreal Ziv-Aflibercept (ZA-IV) is a recombinant fusion protein used to treat macular diseases. Several studies have demonstrated its efficacy and safety. The objective was to evaluate the efficacy and safety of ZA-IV in the treatment of diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion (RVO).

To investigate the association between pretreatment controlling nutritional status (CONUT) score and clinical outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs).

Oral mucositis (OM) is oral mucosal damage caused by cancer treatment, including radiotherapy and chemotherapy. It is a common and debilitating adverse effect with significant impact on the quality of life. Current guidelines recommend various treatments, but the evidence base remains limited, highlighting the need for novel therapeutic approaches. Phytotherapy, including turmeric (Curcuma longa), offers potential due to its antioxidant, anti-inflammatory, antimicrobial, and wound-healing properties, which have shown promise in addressing inflammatory conditions. This systematic review aims to identify and appraise the quality of studies of turmeric/curcumin (T/C) for OM and evaluate its potential effectiveness and safety to inform future research.

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, was developed to overcome resistance from EGFR-mutant non-small-cell lung cancer (NSCLC). While it offers significant therapeutic benefits, reports have linked Osimertinib to cardiotoxic effects. This study aims to clarify the direct cardiotoxicity of Osimertinib by reviewing clinical trials and cohort studies involving Osimertinib monotherapy compared to other EGFR inhibitors. A search was conducted in online databases. Measured outcomes included risk of heart failure (HF), myocardial infarction (MI), decline in left ventricular ejection fraction (LVEF), arrhythmias, and pericardial effusion. These outcomes were reported as risk ratio (RR) with a random effects model using 95% confidence intervals (CI). Five studies with 19,008 patients (age 68 ± 13, 65% female) were selected. Osimertinib therapy was associated with an increased risk of HF (RR = 1.45, 95% CI 1.19-1.76, p = 0.0002), decline in LVEF (RR = 3.10, 95% CI 1.72-5.59, p = 0.0002) and MI (RR = 1.40, 95% CI 1.09-1.79, p = 0.0078) compared to other EGFR inhibitors. There was no difference in the risk of arrhythmias and pericardial effusion. Osimertinib therapy is associated with an increased risk of HF and a decline in LVEF compared to other EGFR inhibitors, while associations with MI and arrhythmias were less consistent. Although these events are infrequent, their potential severity warrants proactive cardiac monitoring for patients receiving Osimertinib, particularly in patients with pre-existing risk factors.

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies.

Bone metastases are a frequent and clinically consequential complication of advanced non-small cell lung cancer (NSCLC), associated with substantial morbidity and poor survival. Whether adding radiotherapy (RT) to immune checkpoint inhibitors (ICIs) improves outcomes remains uncertain.

The systematic review and meta-analysis aim to thoroughly assess the efficacy of manual interventions like massage therapy, reflexology, and acupressure techniques in relation to overall symptoms, pain, and quality of life (QOL) in patients suffering from CIPN.

Autoimmune bullous diseases (AIBDs) constitute a rare yet potentially life-threatening subset of immune-related adverse events induced by immune checkpoint inhibitors (ICIs). However, the characteristics of ICI-induced AIBDs (ICI-AIBDs) and the factors influencing patient survival remain incompletely characterized. Therefore, we aimed to synthesize the available information on ICI-AIBD patients and sought to explore factors potentially influencing the survival outcome of this population.

Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become an important area of clinical investigation in the gastric cancer (GC) and gastroesophageal junction cancer (GEJC). In recent years, bispecific antibody therapies have been increasingly explored, including cadonilimab, a programmed death-1/cytotoxic T-lymphocyte-associated antigen 4 (PD-1/CTLA-4) bispecific antibody. Several phase II studies have reported early signals of antitumor activity with cadonilimab, prompting clinical interest in this strategy. However, treatment outcomes vary across studies, and a systematic assessment of the efficacy and safety of cadonilimab plus chemotherapy remains limited. This study aimed to evaluate the efficacy and safety profile of cadonilimab in combination with chemotherapy for gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (G/GEJ adenocarcinoma) through a single-arm meta-analysis.